Skip to content

Horizon Therapeutics Public Ltd Co

CIK 0001492426

← back to feed
Revenue (TTM)
$3.58B
+12.5% YoY Q2 Aug 2023
Net Income (TTM)
$378.57M
−2.4% YoY Q2 Aug 2023
EPS Diluted (TTM)
$1.61
−2.2% YoY Q2 Aug 2023
Gross Margin
75.1%
Q2 Aug 2023
Operating Margin
12.0%
Q2 Aug 2023
Net Margin
10.6%
Q2 Aug 2023
Free Cash Flow (TTM)
$60.13M
Q2 Aug 2023
Cash
$2.46B
Q2 Aug 2023
Total Debt
$2.56B
Q2 Aug 2023
Shares Outstanding
228.99M sh
Q2 Aug 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings